imdevimab

GPTKB entity

Statements (23)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:administered_by intravenous infusion
gptkbp:approves gptkb:FDA
gptkbp:can_be_combined_with gptkb:bamlanivimab
gptkbp:chemical_formula C6484 H10000 N1716 O2000 S44
gptkbp:clinical_trial Phase 3
gptkbp:developed_by gptkb:Eli_Lilly_and_Company
https://www.w3.org/2000/01/rdf-schema#label imdevimab
gptkbp:indication mild to moderate COVID-19 in high-risk patients
gptkbp:marketed_as the brand name Bamlanivimab/ Etesevimab
gptkbp:mechanism_of_action neutralizes SARS-Co V-2 virus
gptkbp:route_of_administration intravenous
gptkbp:side_effect fatigue
headache
nausea
diarrhea
infusion-related reactions
gptkbp:targets Spike protein of SARS-Co V-2
gptkbp:used_for treatment of COVID-19
gptkbp:bfsParent gptkb:REGEN-COV
gptkb:Regen-Cov
gptkb:REGN-COV2
gptkbp:bfsLayer 5